Press release
Metastatic Castration Sensitive Prostate Cancer Market in 7MM is expected to witness a major change in the study period 2019-2032 | Major Companies- Astellas Pharma, Pfizer, Janssen Pharmaceutical, and Others
DelveInsight's Metastatic Castration Sensitive Prostate Cancer Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies' market shares, challenges, Metastatic Castration Sensitive Prostate Cancer market drivers, barriers, and trends, and key Metastatic Castration Sensitive Prostate Cancer companies in the market.
Download a PDF Sample Report- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Metastatic Castration Sensitive Prostate Cancer Market Report
• The Metastatic Castration Sensitive Prostate Cancer market is expected to grow at a considerable CAGR during the study period from 2019 to 2032.
• As per DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets was 7,726,394 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019-2032.
• As per DelveInsight estimates, treated cases of metastatic CSPC in Japan were 11,094 in 2021.
• Metastatic Castration Sensitive Prostate Cancer market companies are included like Astellas Pharma, Pfizer, Janssen Pharmaceutical, Myovant Sciences, Takeda, Bayer, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Novartis Pharmaceuticals, Ferring Pharmaceuticals, Genentech, Exelixis, and several others.
• Metastatic Castration Sensitive Prostate Cancer market therapies are covered like Xtandi, Erleada, Orgovyx, and several others.
Metastatic Castration Sensitive Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. As per American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
Metastatic Castration Sensitive Prostate Cancer Treatment Market
Treatment options of prostate cancers include mainly hormonal therapies (also known as androgen-deprivation therapy or ADT), chemotherapy, immunotherapy, radiation therapy, and surgery. For localized or locally advanced prostate cancer has active surveillance, surgery, and radiation therapy is the 3 major treatment options. Patients who have never received i.e. are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC).
Metastatic Castration Sensitive Prostate Cancer Epidemiology Segmentation in the 7MM
• Total Metastatic Castration Sensitive Prostate Cancer Prevalent Cases
• Total Metastatic Castration Sensitive Prostate Cancer Diagnosed Cases
• Metastatic Castration Sensitive Prostate Cancer Age-specific Cases
• Total Metastatic Castration Sensitive Prostate Cancer Diagnosed Cases by Clinical Stage
• Total Metastatic Castration Sensitive Prostate Cancer Metastatic Cases
• Total Metastatic Castration Sensitive Prostate Cancer Treated Cases
Metastatic Castration Sensitive Prostate Cancer Market
Metastatic Castration Sensitive Prostate Cancer market is expected to witness a significant growth rate owing to rising prevalence of Metastatic Castration Sensitive Prostate Cancer cases due to rapidly aging population and growing awareness among people, market penetration in Metastatic Castration Sensitive Prostate Cancer due to label expansion, and entry of new emerging therapies.
Discover more information about the report offering- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Castration Sensitive Prostate Cancer Marketed Drugs
• Xtandi (Pfizer)
• Erleada (Janssen Pharmaceutical)
• Orgovyx (Myovant Sciences)
Metastatic Castration Sensitive Prostate Cancer Emerging Drugs
• Talazoparib (Pfizer)
• Nubeqa (Bayer)
• Niraparib (Janssen)
• Keytruda (Merck Sharp & Dohme)
• Rubraca (Clovis Oncology)
Metastatic Castration Sensitive Prostate Cancer Market Companies
• Astellas Pharma
• Pfizer
• Janssen Pharmaceutical
• Myovant Sciences
• Takeda
• Bayer
• Merck Sharp & Dohme
• Clovis Oncology
• Bristol-Myers Squibb
• Novartis Pharmaceuticals
• Ferring Pharmaceuticals
• Genentech
• Exelixis, and several others
Metastatic Castration Sensitive Prostate Cancer Market
It is anticipated to provide a major push to the growth of the Metastatic Castration Sensitive Prostate Cancer market size in the study period 2019-2032 in the 7MM. Furthermore, extensive R&D in the domain along with increasing Metastatic Castration Sensitive Prostate Cancer prevalence is also driving the growth of the Metastatic Castration Sensitive Prostate Cancer market size ahead.
Request a PDF Sample Report- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of content
1. Key Insights
2. Report Introduction
3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Overview at a Glance
4. Executive Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. SWOT Analysis
8. Disease Background and Overview
9. Diagnosis of Prostate Cancer
10. Treatment and Management of Prostate Cancer
11. American Urological Association (AUA) Guidelines for mHSPC: 2020
12. Guidelines for mHSPC: Abiraterone acetate combined with castration is another standard (European Association of Urology, 2018)
13. National Institute for health and care excellence (NICE) Recommendation Guidelines for mCSPC/mHSPC: 2022
14. SEOM Clinical Guidelines for mCSPC/mHNPC: 2021
15. Updated NCCN Guidelines for mCSPC
16. Epidemiology and Patient Population
17. Organizations contributing towards Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
18. Metastatic Castration-Sensitive Prostate Cancer Marketed Therapies
19. Metastatic Castration-Sensitive Prostate Cancer Emerging Therapies
20. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Seven Major Market Analysis
21. Metastatic Castration-Sensitive Prostate Cancer Market Drivers
22. Metastatic Castration-Sensitive Prostate Cancer Market Barriers
23. Unmet Needs
24. Reimbursement and Market Access
25. Appendix
26. Report Methodology
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight
Do you have any query related to the report? If yes, click here- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration Sensitive Prostate Cancer Market in 7MM is expected to witness a major change in the study period 2019-2032 | Major Companies- Astellas Pharma, Pfizer, Janssen Pharmaceutical, and Others here
News-ID: 3007698 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
